PPIDT00370
Drug Information
| Name | Cerliponase alfa |
|---|---|
| Sequence | SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP |
| DrugBank_ID | DB13173 |
| Type | biotech |
| Indication | Cerliponase alfa is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.[L51319, L51324, L51329] It is approved for use in children in the US, whereas in Europe and Canada, it is approved for use in patients of all ages. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intracerebral |
150 mg
|
| Injection, solution | Intracerebral; Parenteral |
150 MG
|
| Injection, solution; kit | Intraventricular |
150 mg/5mL
|
| Solution | Intracerebral |
150 mg / 5 mL
|
| Solution | Intracerebral |
3000000 mg
|